Application/Control Number: 09/859,463

Art Unit: 1600

CLMPTO

M.M.

5/18/01

- 1. (Amended) A compound comprising a superoxide dismutase and an organic nitrate or nitrite moiety.
- 2. (Amended) A compound according to claim 1, which is represented by formula (I):

(A)n(B)m (I)

where A is a superoxide dismutase, B is an organic nitrate or mirite moiety, and a and m are values between 1 and 8.

Claims 3-8 (Original)

- 3. A compound according to claim 2, wherein in formula (1), n and m are integers.
- 4. A compound according to claim 3, wherein the values of a and m are both 1.
- . 0 0 0 0 A compound according to claim 2 wherein A and B are stably linked.
 - A compound according to claim 2, wherein said organic nitrate or nitrite moiety forms nitric oxide in the body of an animal.
- Į. A compound according to claim 6, wherein the nitric oxide is formed by enzymatic conversion of said organic nitrate or nitrite molety by endogenous enzymes in the () · body of an animal. 69 68 58
- 8. A compound according to claim 7, wherein said enzymatic conversion is by xauthing exidase.

Art Unit: 1600

- 9. (Amended) A compound according to claim 6, wherein the superoxide dismutase remains effective in trapping superoxide upon enzymatic conversion of the organic nitrate or nitrite moiety to form nitric oxide.
- 10. (Amended) A compound according to claim 2, wherein the superoxide dismutase is a low molecular mass superoxide dismutase analog.
- (Amended) A compound according to claim 2, wherein the superoxide dismutase 12 contains one or more thiol groups.
- (Amended) A compound according to claim 2, wherein said superoxide dismutase is 13. linked to the organic nitrate or mitrite moiety by a linkage that is stable under physiological conditions.

Claims 14-17 (Original)

- A compound according to chain 13, wherein said linkage is a thiol linkage. 14.
- A compound having the formula

- A composition comprising a compound according to claim 2 in conjunction with a 16. pharmaceatically-acceptable excipient.
- A method of treating heart disease comprising administering a compound according to 17. claim 2 in a therapeutically effective amount to a patient in need thereof.